These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
398 related articles for article (PubMed ID: 33242418)
1. Direct Tumor Killing and Immunotherapy through Anti-SerpinB9 Therapy. Jiang L; Wang YJ; Zhao J; Uehara M; Hou Q; Kasinath V; Ichimura T; Banouni N; Dai L; Li X; Greiner DL; Shultz LD; Zhang X; Sun ZJ; Curtin I; Vangos NE; Yeoh ZC; Geffken EA; Seo HS; Liu ZX; Heffron GJ; Shah K; Dhe-Paganon S; Abdi R Cell; 2020 Nov; 183(5):1219-1233.e18. PubMed ID: 33242418 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of SerpinB9 to enhance granzyme B-based tumor therapy by using a modified biomimetic nanoplatform with a cascade strategy. Han R; Yu L; Zhao C; Li Y; Ma Y; Zhai Y; Qian Z; Gu Y; Li S Biomaterials; 2022 Sep; 288():121723. PubMed ID: 35963816 [TBL] [Abstract][Full Text] [Related]
3. The biological function of Serpinb9 and Serpinb9-based therapy. Huang H; Mu Y; Li S Front Immunol; 2024; 15():1422113. PubMed ID: 38966643 [TBL] [Abstract][Full Text] [Related]
5. A Novel Serpin Regulatory Mechanism: SerpinB9 IS REVERSIBLY INHIBITED BY VICINAL DISULFIDE BOND FORMATION IN THE REACTIVE CENTER LOOP. Mangan MS; Bird CH; Kaiserman D; Matthews AY; Hitchen C; Steer DL; Thompson PE; Bird PI J Biol Chem; 2016 Feb; 291(7):3626-38. PubMed ID: 26670609 [TBL] [Abstract][Full Text] [Related]
6. A novel Granzyme B nanoparticle delivery system simulates immune cell functions for suppression of solid tumors. Qian X; Shi Z; Qi H; Zhao M; Huang K; Han D; Zhou J; Liu C; Liu Y; Lu Y; Yuan X; Zhao J; Kang C Theranostics; 2019; 9(25):7616-7627. PubMed ID: 31695790 [TBL] [Abstract][Full Text] [Related]
7. The granzyme B-Serpinb9 axis controls the fate of lymphocytes after lysosomal stress. Bird CH; Christensen ME; Mangan MS; Prakash MD; Sedelies KA; Smyth MJ; Harper I; Waterhouse NJ; Bird PI Cell Death Differ; 2014 Jun; 21(6):876-87. PubMed ID: 24488096 [TBL] [Abstract][Full Text] [Related]
12. The role of serpinb9/serine protease inhibitor 6 in preventing granzyme B-dependent hepatotoxicity. Stout-Delgado HW; Getachew Y; Rogers TE; Miller BC; Thiele DL Hepatology; 2007 Nov; 46(5):1530-40. PubMed ID: 17685438 [TBL] [Abstract][Full Text] [Related]
13. Control of granzymes by serpins. Kaiserman D; Bird PI Cell Death Differ; 2010 Apr; 17(4):586-95. PubMed ID: 19893573 [TBL] [Abstract][Full Text] [Related]
14. Reprogramming Tumor-Associated Macrophages by Antibody Targeting Inhibits Cancer Progression and Metastasis. Georgoudaki AM; Prokopec KE; Boura VF; Hellqvist E; Sohn S; Östling J; Dahan R; Harris RA; Rantalainen M; Klevebring D; Sund M; Brage SE; Fuxe J; Rolny C; Li F; Ravetch JV; Karlsson MC Cell Rep; 2016 May; 15(9):2000-11. PubMed ID: 27210762 [TBL] [Abstract][Full Text] [Related]
15. A pro-survival role for the intracellular granzyme B inhibitor Serpinb9 in natural killer cells during poxvirus infection. Mangan MS; Melo-Silva CR; Luu J; Bird CH; Koskinen A; Rizzitelli A; Prakash M; Scarff KL; Müllbacher A; Regner M; Bird PI Immunol Cell Biol; 2017 Nov; 95(10):884-894. PubMed ID: 28722018 [TBL] [Abstract][Full Text] [Related]
16. Nanocarrier-Mediated Chemo-Immunotherapy Arrested Cancer Progression and Induced Tumor Dormancy in Desmoplastic Melanoma. Liu Q; Chen F; Hou L; Shen L; Zhang X; Wang D; Huang L ACS Nano; 2018 Aug; 12(8):7812-7825. PubMed ID: 30016071 [TBL] [Abstract][Full Text] [Related]
17. Activatable Immunoprotease Nanorestimulator for Second Near-Infrared Photothermal Immunotherapy of Cancer. Xu M; Zhang C; He S; Xu C; Wei X; Pu K ACS Nano; 2023 May; 17(9):8183-8194. PubMed ID: 37122103 [TBL] [Abstract][Full Text] [Related]
18. FAP Delineates Heterogeneous and Functionally Divergent Stromal Cells in Immune-Excluded Breast Tumors. Cremasco V; Astarita JL; Grauel AL; Keerthivasan S; MacIsaac K; Woodruff MC; Wu M; Spel L; Santoro S; Amoozgar Z; Laszewski T; Migoni SC; Knoblich K; Fletcher AL; LaFleur M; Wucherpfennig KW; Pure E; Dranoff G; Carroll MC; Turley SJ Cancer Immunol Res; 2018 Dec; 6(12):1472-1485. PubMed ID: 30266714 [TBL] [Abstract][Full Text] [Related]
19. Melittin-MIL-2 fusion protein as a candidate for cancer immunotherapy. Liu M; Wang H; Liu L; Wang B; Sun G J Transl Med; 2016 Jun; 14(1):155. PubMed ID: 27246873 [TBL] [Abstract][Full Text] [Related]